Co-Diagnostics, Inc.: directors' dealings · United States · SEC (Form 4)

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a US-based molecular diagnostics company listed on the NASDAQ market in the United States. The company was founded in 2013 and is incorporated in Utah, with its headquarters in Salt Lake City. Its operating footprint is centered on product development, laboratory work, and corporate support functions from that base. Co-Diagnostics’ core investment thesis is built around a proprietary PCR assay-design platform that the company uses to develop molecular diagnostic tests, with an emphasis on nucleic-acid detection and test performance. In regulatory and investor disclosures, the company highlights its patented technology as the foundation of its competitive positioning. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1692415/000147793218001468/codx_10k.htm?utm_source=openai)) From a business-line perspective, Co-Diagnostics focuses on reagents and diagnostic tests that detect and analyze DNA and RNA. A key commercial and strategic initiative is the Co-Dx PCR Pro platform, which combines a PCR instrument, a proprietary test cup system, and a mobile application. This platform is intended to support decentralized molecular testing and faster diagnostics, areas where differentiation through intellectual property, workflow simplification, and assay design can matter materially. The company has also described potential applications beyond infectious disease diagnostics, including precision medicine and agricultural testing, which broadens the addressable opportunity set, although these initiatives should still be viewed as development-oriented rather than large-scale, established revenue engines. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1692415/000164117225000932/form10-k.htm?utm_source=openai)) In competitive terms, Co-Diagnostics remains a niche small-cap player rather than a broad diagnostics leader. Its competitive advantage is less about scale and more about technology ownership, patent protection, and the ability to convert its assay-design capabilities into commercial products or licensing arrangements. Larger diagnostics companies typically benefit from stronger distribution networks, broader menus, and deeper clinician relationships, so Co-Diagnostics must continue proving both technical merit and market adoption. The company’s headquarters and primary operational infrastructure are in Salt Lake City, and its SEC disclosures indicate that it has pursued international commercial activities and partnerships as part of its growth strategy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1692415/000149315220005305/form10-k.htm?utm_source=openai)) Recent developments remain important for investors. In 2025, Co-Diagnostics said it had withdrawn an FDA submission for the Co-Dx PCR Pro platform, with plans to submit an enhanced version of the test and instrument for 510(k) clearance. That suggests the product roadmap is still navigating regulatory refinement before broad commercialization. In addition, SEC Form 4 filings in May 2025 show insider transaction activity, which is often monitored closely by market participants because it can provide context on management’s ownership changes and near-term signaling. Overall, CODX is best characterized as an innovation-driven diagnostics name with meaningful optionality, but also with regulatory, commercial, and execution risks that remain elevated versus more mature public diagnostics peers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1692415/000164117225000922/ex99-1.htm?utm_source=openai))